Tasly Pharmaceutical Group's (SHA:600535) unit, Tasly Biopharmaceutical, received a drug registration certificate from the Chinese drug administration for recombinant human prourokinase for injection, according to a Tuesday disclosure on the Shanghai bourse.
The drug, with the brand name Puyouke, is a thrombolytic treatment of acute ischemic stroke.
The Chinese pharmaceutical company invested 329.3 million yuan into the research and development of the drug.
The company's shares rose over 2% during the morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments